I can't totally agree on your logic there: R&D, what for? renal? And the new directors have apparently come onboard due to shareholders animosity over the recent capital rasie to fund the 'opportunity to get sales after the NCCN Guidelines inclusion".
I think I can attiribute most of the recent price drop to a bit of a snowball event of agnst against the director spill action and hartists activity combined. But I am confident of a rebound when we see the results of sales which hopefully won't be too far away. If the sales numbers disappoint then a fall below the recent capitol raising price is on the cards/charts too - ha ha ha - %$&# the charts anyway.
I can't totally agree on your logic there: R&D, what for? renal?...
Add IPD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $161.8M | |||
| Open | High | Low | Value | Volume |
| 8.1¢ | 8.2¢ | 8.0¢ | $104.8K | 1.309M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 166577 | 8.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.1¢ | 100000 | 1 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
8.1¢ |
Change
0.000 ( 1.25 %) |
||||
| Open | High | Low | Volume | ||
| 8.0¢ | 8.1¢ | 8.0¢ | 135749 | ||
| Last updated 12.21pm 03/05/2024 ? | |||||
| IPD (ASX) Chart |